The value of comprehensive genomic sequencing to maximize the identification of clinically actionable alterations in advanced cancer patients: a case series.

ABSTRACT:

Purpose

We present seven cases of advanced cancer patients who initially underwent tumor testing utilizing smaller, panel-based tests, followed by a variety of therapeutic treatments which ultimately resulted in progression of their disease. These cases demonstrate the value of utilizing WES/RNA seq and characterization following disease progression in these patients and the determination of clinically targetable alterations as well as acquired resistance mutations.

Materials and methods

All patients are part of an IRB approved observational study. WES and RNA sequencing were performed, using GEM ExTra^® on tumor and blood samples obtained during routine clinical care. To accurately determine somatic versus germline alterations the test was performed with paired no

SUBMITTER: Drenner K 

PROVIDER: S-EPMC8416559 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature